title: [The use of akatinol memantine in the residual phase of stroke].
abstract: Fifty patients who had had left-hemisphere stroke 1-12 months before the inclusion in the study were examined. All patients underwent the 90-day course of neurorehabilitation. Forty patients of the main group received akatinol memantine as an add-on drug during 90 days in the initial dosage 5-10 mg/day with the gradual increase to 20 mg/day (10 mg twice a day); the control group included 10 patients. Comparative efficacy of neurorehabilitation was assessed 1,5 and 3 months after treatment with clinical scales NIHSS and Barthel, testing of higher mental functions with 10-score original digital scale (V.M. Shklovsky et al), neurophysiological study (electroencephalography and constant brain potentials). The distinct effect of akatinol memantine on the restoration of higher mental functions and, to a less extent, on the movement deficit was seen. The dynamic neurophysiological study revealed that the addition of akatinol memantine to the neurorehabilitation course activates reserve possibilities of the left hemisphere in small or moderate poststroke lesions. The trend toward the association between the efficacy and the time since stroke onset and the intensity of rehabilitation measures was found.
authors.forename: E V
authors.initials: EV
authors.lastname: Luk'ianiuk
authors.forename: N G
authors.initials: NG
authors.lastname: Maliukova
authors.forename: V M
authors.initials: VM
authors.lastname: Shklovskiĭ
authors.forename: Kh S
authors.initials: KhS
authors.lastname: Saiadian
mesh_terms: D000328:Adult; D000368:Aged; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000627:therapeutic use*; D008875:Middle Aged; D012720:Severity of Illness Index; D020521:Stroke / Q000503:physiopathology / Q000523:psychology; D000071939:Stroke Rehabilitation; D016896:Treatment Outcome
chemical_list: D008559:Memantine